Abstract
The aim of these studies was to determine if photodynmaic therapy with Vertepofin can safely reduce the risk of vision loss in patients with subfoveal, choroidal neovascularization (CNV) secondary to age related macular degeneration (TAP trial) and pathologic myopia (VIP trial).
© 2000 IEEE
PDF ArticleMore Like This
Sergey E. Avetisov, Maria V. Budzinskaja, Tatyana N Kiseleva, Natalia V. Balatskaya., Irina V. Gurova., Victor B. Loschenov, Sergey A. Shevchik, Sergey G. Kuzmin, and Georgy N. Vorozhtsov
6632_63 European Conference on Biomedical Optics (ECBO) 2007
Ursula M. Schmidt-Erfurth
CWA1 Biomedical Topical Meeting (BIOMED) 1999
Ann E. Elsner, Giovanni Staurenghi, John J. Weiter, Sheldon M. Buzney, Sebastian Wolf, and Kenneth J. Wald
NMB.5 Noninvasive Assessment of the Visual System (NAVS) 1993